v3.26.1
Note 1 - Business and Organization (Details Textual)
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2017
Number of Wholly-Owned Subsidiaries 5   5      
Revenue from Contract with Customer, Including Assessed Tax $ 1,248,000 $ 2,777,000 $ 2,363,000 $ 6,046,000    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (4,000,000) $ (1,882,000) (7,405,000) (3,803,000)    
Cash Provided by (Used in) Operating Activity, Discontinued Operation     (5,973,000)      
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation     4,469,000 $ 3,699,000    
Assets, Current 3,499,000   3,499,000   $ 5,114,000  
Cash and Cash Equivalent 2,188,000   2,188,000   3,883,000  
Liabilities, Current 4,765,000   4,765,000   $ 5,063,000  
Working Capital (Deficit) $ 1,266,000   $ 1,266,000      
Clyra Medical Technologies [Member]            
Subsidiary, Ownership Percentage, Parent 48.00%   48.00%      
BioLargo Engineering, Science & Technologies, LLC [Member]            
Subsidiary, Ownership Percentage, Parent 70.00%   70.00%     100.00%
BioLargo Energy Technologies, Inc (BETI) [Member]            
Subsidiary, Ownership Percentage, Parent 94.00%   94.00%      
BioLargo Consumer Products Group (BCPG) [Member]            
Subsidiary, Ownership Percentage, Parent 78.00%   78.00%